Tyvaso DPI is a drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler. The Food and Drug Administration (FDA) has approved ...

The US Food and Drug Administration (FDA) on Wednesday published a revised draft guidance on metered dose inhalers (MDIs) and dry powder inhalers (DPIs), offering recommendations on chemistry, ...

Researchers in the United Kingdom compared the potential impact on carbon footprint and asthma symptom control of switching maintenance therapy to a dry powder inhaler vs continuing with a metered ...

Patients who switched from a pressurized metered dose inhaler (pMDIs) to a dry powder inhaler (DPI) halved their carbon footprints while still maintaining good asthma control, a post-hoc analysis of ...

Switching asthma patients from a pressurised metered dose inhaler (pMDI) to a dry powder inhaler (DPI) for maintenance therapy more than halves their carbon footprint without loss of asthma control, ...

Dry powder inhalers (DPIs) have become a mainstay in the management of chronic pulmonary diseases such as chronic obstructive pulmonary disease and asthma. Their performance depends on a complex ...

Shares of MannKind Corporation (MNKD) added ~16% in the premarket on Wednesday after the company announced plans for a new jointly developed therapy as part of an expanded license and collaboration ...

The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ...

Please provide your email address to receive an email when new articles are posted on . A metered-dose inhaler was switched to a dry-powder inhaler in July 2021 in Veterans Affairs facilities. The ...

United Therapeutics UTHR announced that the FDA has issued a complete response letter to its new drug application (“NDA”) for its drug device combination therapy, Tyvaso Dry Powder Inhaler or Tyvaso ...